KCNJ3
G protein-activated inward rectifier potassium channel 1
As of the edition of 20 October 2026, KCNJ3 (G protein-activated inward rectifier potassium channel 1, UniProt P48549) has 2 drugs tested at it and 4 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P48549
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Heart and blood vessels
- Registered trials of its drugs
- 15
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vernakalant | Marketed | Phase 4 | none listed |
| AZD-2927 | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Undetermined | 3 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
The other 3 companies at KCNJ3
In the product4 companies in all; 3 are not named here, and no score is.
See the 4 companies at KCNJ3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.